Ilmarinen Mutual Pension Insurance Co Has $8.12 Million Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Ilmarinen Mutual Pension Insurance Co raised its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 42.5% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,400 shares of the biopharmaceutical company’s stock after acquiring an additional 3,400 shares during the period. Ilmarinen Mutual Pension Insurance Co’s holdings in Regeneron Pharmaceuticals were worth $8,121,000 at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of REGN. Intact Investment Management Inc. acquired a new position in Regeneron Pharmaceuticals in the fourth quarter valued at about $356,000. Principal Financial Group Inc. raised its position in shares of Regeneron Pharmaceuticals by 1.7% in the 3rd quarter. Principal Financial Group Inc. now owns 173,092 shares of the biopharmaceutical company’s stock valued at $181,961,000 after buying an additional 2,828 shares in the last quarter. Fagan Associates Inc. raised its position in shares of Regeneron Pharmaceuticals by 42.2% in the 4th quarter. Fagan Associates Inc. now owns 12,923 shares of the biopharmaceutical company’s stock valued at $9,205,000 after buying an additional 3,832 shares in the last quarter. Golden State Equity Partners lifted its holdings in shares of Regeneron Pharmaceuticals by 1,479.1% during the 4th quarter. Golden State Equity Partners now owns 1,358 shares of the biopharmaceutical company’s stock worth $967,000 after acquiring an additional 1,272 shares during the period. Finally, ABC Arbitrage SA acquired a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter worth approximately $1,510,000. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Price Performance

Shares of REGN opened at $573.45 on Friday. The business has a 50-day moving average of $676.70 and a 200-day moving average of $779.13. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. The company has a market capitalization of $62.69 billion, a price-to-earnings ratio of 14.98, a price-to-earnings-growth ratio of 2.34 and a beta of 0.44. Regeneron Pharmaceuticals, Inc. has a 1 year low of $572.00 and a 1 year high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The firm had revenue of $3.79 billion during the quarter, compared to analyst estimates of $3.76 billion. During the same quarter last year, the business earned $11.86 EPS. The company’s revenue was up 10.3% compared to the same quarter last year. As a group, equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Thursday, March 20th. Investors of record on Thursday, February 20th were issued a $0.88 dividend. The ex-dividend date was Thursday, February 20th. This represents a $3.52 annualized dividend and a yield of 0.61%. Regeneron Pharmaceuticals’s payout ratio is 2.30%.

Analyst Upgrades and Downgrades

Several brokerages have commented on REGN. Citigroup lowered their price objective on shares of Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating for the company in a research report on Tuesday, January 28th. Truist Financial lowered their price target on Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating for the company in a report on Wednesday, January 8th. BMO Capital Markets reduced their price objective on Regeneron Pharmaceuticals from $950.00 to $903.00 and set an “overweight” rating on the stock in a research note on Tuesday, February 4th. TD Cowen lowered their target price on Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating for the company in a research note on Tuesday, February 4th. Finally, Leerink Partners raised shares of Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and increased their target price for the stock from $762.00 to $834.00 in a report on Wednesday, February 5th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $966.88.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.